Pre-/Probiotics and Akkermansia Muciniphila: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Subjects: Gastroenterology & Hepatology
Contributor:
Simona Bungau

This entry highlights the following main aspects: the relationship between probiotics/gut microbes with the pathogenesis of MetS, the particular positive roles of Akkermansia muciniphila supplementation in the onset of MetS, and the interaction between dietary polyphenols (prebiotics) with gut microbiota.

  • prebiotics
  • probiotics
  • metabolic syndrome
  • type 2 diabetes mellitus
  • Akkermansia muciniphila
  • gut bacterium

1. Introduction

The only Gram-negative emblematic Verrucomicrobia that is widespread in human intestinal mucosa is A. muciniphila [1]. Gene sequence analyses revealed that there are multiple gene candidates for mucin encoding and the single chromosome is contained in 2176 genes with a 55.8% GC content after the MucT type strain of A. muciniphila, as reported by Derrien (ATCC BAA-835 1/4 CIP107961T) [2][3]. This non-motile, oval-formed microorganism is purely anaerobic and with chemical organotrophic material that can withstand low levels of oxygen. A. muciniphila may create mucin-degrading enzymes and use mucin in the mucosal layer of the epithelium as a source of carbon and nitrogen. A. muciniphila splits these compounds into acetic and propionic compounds, releasing sulfate [4][5]. A. muciniphila also is 3 to 5% of the total gut microbiome population in healthy adult humans based on an analysis of its distinctive 16SrRNA signature, although this amount differs by several factors. In stable human beings, A. muciniphila has been closely linked to age. Its colonization starts at a young age and ranges between 5.0 and 8.8 log cells/g in a year equivalent to the adult stage but decreases in the elderly [6][7]. In comparison, in patients with metabolic disorders, A. muciniphila and a mucosal pathology varied, and the incidence of appendicitis and IBD was reversely associated with this [8]. In addition, a negative association of intestinal A. muciniphila with diabetes, obesity, and others MetS has been shown [9].

Dual control of A. muciniphila and metabolic disorders has demonstrated that both A. muciniphila excess and supplementation can have an effect on the host body. The anatomy of A. muciniphila can also be affected. The dissemination of A. muciniphila through early vancomycin therapy to the early intestinal colonization could help regulate the progression of autoimmune diabetes [10]. In an initial analysis, A. muciniphila was recognized as a potential new therapeutic agent for obese patients. Most studies have shown the advantages of using A. muciniphila in metabolic and obesity disorders for prevention and progress. T2DM is characterized by a lower A. muciniphila abundance, low inflammation, and an intestinal permeability disease [11]. The degree of A. muciniphila development can be used to determine the metabolic state of the body, for instance glucose homeostasis, serum lipids, and human adipocyte distribution. The reason for associating A. muciniphila with the production of obesity is not yet entirely explained. We have therefore analyzed the most recent studies into A. muciniphila’s function in obesity and learned more about its effects on the distinctive changes in the expression of pathways in metabolic homeostasis [12].

2. A. muciniphila and Obesity: Evidence from Mouse Models

All of the previous studies found a correlation between the caloric intake of A. muciniphila and its abundance. Prebiotic administration in high-fat diet mice eliminated the metabolic endotoxemia that characterizes the compromised MetS present among obese participants, decreased the overall fat mass, and decreased body weight [13]. These findings have in fact been strongly linked to an abundance of A. muciniphila [14]. The reduction of A. muciniphila and inflammatory markers were crucial in all circulatory parameters (i.e., glucose, insulin, leptin, and triglycerides), with 118 of the 13 genes implicated in the fatty oxidation, production, and oxidation of positive ties, whereas Bifidobacterium spp. were important. Three inflammatory features, leptin, and only two genes involved in the oxidation of fatty compounds are positively and negatively related.

Schneeberger et al. documented the inversely related levels of A. muciniphila in mice with inflammatory markers, lipid synthesis and insulin tolerance, cardiovascular risk, and adiposity markers in their plasma. After six consecutive weeks of HFD administration, the main effects were body weight gain and adiposity in mice. The results therefore suggest that an HFD particularly affects the gut bacteria and show that the abundance of A. muciniphila is decreasing steadily with sustained dietary care in mice. This bacterium also reduces, showing a causal impact, the disease development before the initiation of metabolic changes [15]. In comparison, the abundance of A. muciniphila increases and decreases in mice fed a diet rich in fish oil and lard, with greater regulation of the intestinal barrier system and less inflammatory tissue, which can be converted into germless receiving mice [16]. Other authors also found that the gut barrier dysfunction, weight, and fat gain of HFD-fed mice can be decreased at the same time with A. muciniphila [17][18]. The relation between age and A. muciniphila was finally identified in mice, as the intestinal level of the bacterium is lower in older mice. An HFD improves the adipose tissue and intestinal microbiological composition considerably compared to aging [15].

3. A. muciniphila and Obesity: Evidence from Human Studies

Emerging research assessed the correlation between A. muciniphila intestinal abundance and human body weight. There are proofs that these two variables have an opposite correlation [19][20]. The numbers of Bifidobacterium spp. and A. muciniphila and the number of Staphylococcus spp., Enterobacteriaceae spp., and Escherichia coli were found to decrease in overweight pregnancy. They were analyzed by quantitative real-time PCR for their gut microbiota composition. The increase in overall bacteria and Staphylococcus was linked in the whole population with increased plasma cholesterol levels, while the increased amount of Bacteroidites spp. was associated with an increased level of HDL and folic acid [21].

Twenty overweight or obese children and 20 average regular weight children aged 4–5 years were evaluated by Karlsson et. al. Interestingly, in obese/oversized infants, the A. muciniphila levels have decreased dramatically, whereas in the same class, the Gram-negative Enterobacteriaceae concentrations were significantly higher. Bifidobacterium levels in obese/overweight children were inversely linked to alanine aminotransferase (ALT) [22]. Since diabetes and overweight are linked to increased intestinal permeability and low inflammation, endotoxemia caused by LPS is considered as one of the causative agents of obesity-related metabolic disorders. An in vitro observation that confirms the epithelial barrier role of A. muciniphila may provide a working hypothesis to streamline in vivo proof that links decreased fecal A. muciniphila with diabetes and obesity rate. This could reveal a mechanism for protecting HFD obese mice from bacterial LPS endotoxemia. No relationship was currently assessed between A. muciniphila and hypothalamic food intake regulation markers. According to all data, it can be concluded that A. muciniphila influences the reaction of humans in terms of improving inflammation, insulin resistance, and glycemia on their diet of caloric constraint [23].

4. A. muciniphila Medicinal Role in the Treatment of Metabolic Conditions

The study of A. muciniphila has contributed to a better understanding of its possible therapeutic effects and actions in determining certain diseases and metabolic disorders. A. muciniphila, in particular, tends to be involved in the development of amine butyrate and in the propionate extracellular pool. It is also important in the development of sulfide hydrogen, which can be anti-inflammatory and a powerful antioxidant [24][25]. The involvement of A. muciniphila in metabolism enhances prebiotic intake. Both studies performed on animals with A. muciniphila revealed that it decreases body weight and fat mass rise, hepatic steatosis, inflammation, cholesterol, and atherosclerosis; it also enhances insulin sensitivity and restores intestinal barrier function by influencing various factors, such as the thickness of the mucosal membrane, close attachment proteins, antimicrobial peptides, and immunity. A. muciniphila works in particular on the immunomodulatory involvement of a special protein called Amuc 1100 [26].Ottman et al. recently documented the increase of glucose resistance and a decline in body weight and fat gain in mice fed an HFD relative to the untreated mice with refined recombinant Amuc 1100 protein. The critical role of A. muciniphila in intestinal health, particularly in metabolic immunomodulation, is evident in this scenario. In order to increase their therapeutic application to gastrointestinal disease, future studies will also need to accentuate the main role of this microorganism and of its proteins in metabolic regulation and immune modulation [27].The clinical studies focused on the obesity implying A. muciniphila and its associated biomarkers are presented in Table 1.

Table 1. Clinical studies of obesity implying A. muciniphila and its associated biomarkers.

Patients Included in the Study/Condition/Period of Study Observations Results Ref.
81/T2DM/3 months A reduced-energy diet Consumption of A. muciniphila according to dietary portfolio improved levels and strengthened glycemic regulation, dyslipidemia, and inflammation. [28]
60/overweight + obese diabetes/45 days 600 mg butyrate + 10 g inulin/day powder, or placebo Insulin + butyrate supplementation may increase A. muciniphila, and butyrate lowers the expression of TNF-alpha mRNA, hs-CRP, MDA, and DBP. [29]
28 men/obese + metabolic syndrome/35 days 1 g resveratrol orally, 2/day or placebo Resveratrol increases homeostasis of glucose and A. muciniphila abundance. [30]
134 prediabetes
134 healthy controls		 Observation There was a strong decline in the concentration of the mucin-degrading bacterium A. muciniphila in prediabetes. [31]
49/overweight + obese/12 weeks Calorie restriction for 6 weeks The large amounts of A. muciniphila increased the distribution of fasting plasma glucose, plasma triglycerides, and body fat. [12]
43/hypercholesterolemic 19 healthy controls/2 years 27 patients with Atorvastatin treatment Treatment with atorvastatin improved the amount of A. muciniphila. [32]
70 female patients/T2DM
70 healthy females.		 Observation Decreased A. muciniphila was linked with fasting blood/urinary glucose. [33]
16 infants/obese mothers 256 infants/normal mothers as control Observation Prevalence of A. muciniphila was lower in control infants with normal mothers. [21][34][35]
28/diabetes
84 healthy controls		 Metformin Patients with diabetes who obtained metformin have a higher relative abundance of A. muciniphila vs. healthy controls. [36]
13/morbidly obese patients/12 months Roux-en-Y gastric bypass (RYGB) Within the first 3 months, RYGB modified the relative abundances of 31 species, including A. muciniphila. This increase in abundance can be continued for 9 months. [37]
53 women/obesity Observation There were 140 metagenomic species associated with metabolic markers, including A. muciniphila. [17]
21/T2DM/12 months Duodenal-jejunal by-pass surgery medical care In the surgery control group, the amount of gut A. muciniphila increased. [38][39]
32/overweight + obese insulin-resistant/3 months Oral supplementation of 1010 A. muciniphila bacteria, live or pasteurized For liver dysfunction and inflammation, A. muciniphila decreased body weight and decreased the levels of the related blood markers, although the overall composition of the gut microbiota remained unchanged. [40]
21/alcoholic steatohepatitis
16/healthy controls		 Observation The concentration of fecal A. muciniphila vs. healthy controls (indirectly related to the incidence of hepatic disease) was diminished in ASH patients. [41]
13/overweight adults/7 weeks Interventional, fasting (1 week), followed by probiotic intake (6 weeks)
Samples: feces, T1 = before fasting, T2 = during fasting, T3 = 6 weeks after probiotic intervention		 In comparison to fasting (T2), the concentration of A. muciniphila was higher before fasting (T1) than after probiotic action (T3) [13]
3c/normal weight
3/morbid obesity
3/after gastric bypass surgery		 Interventional, gastric bypass Reduced quantity of A. muciniphila in obese subjects (who obtained an elevated quantity of A. muciniphila after gastric bypass) vs. average weight subjects [42]
11/colorectal cancer
10/healthy		 Observational Increased A. muciniphila level in colorectal cancer patients vs. in healthy subjects [43]
71/T2DM
74/healthy controls		 Increased A. muciniphila
abundance in T2DM patients’ feces, vs. in healthy controls patients		 [44]
53/obese women No correlation of A. muciniphila abundance with dyslipidemia/insulin resistance [17]
Children (4–5-year-old)
20/normal weight
20/overweight
20/obesity		 Reduced A. muciniphila abundance in overweight/obese vs. in normal weight children [22]
Pre-diabetes/newly diagnosed T2DM:
44/normal
64/pre-diabetes
13/T2DM		 Reduced A. muciniphila abundance in patients with pre-diabetes/T2DM vs. subjects with regular glucose resistance [45]
23/autistic children Reduced A. muciniphila abundance in autistic children’ feces [7]
Overweight/obese adults
10/normal weight
10/overweight
10/obesity		 No correlation of A. muciniphila level had with the value of BMI [46]

Legend: BMI—body mass index; DPB—diastolic blood pressure; T2DM—type 2 diabetes mellitus.

A summary of the beneficial effects of A. muciniphila treatment on MetS conditions is schematized in Figure 1.

Microorganisms 09 00618 g002 550

Figure 1. A. muciniphila’s benefits in MetS.

This entry is adapted from the peer-reviewed paper 10.3390/microorganisms9030618

References

  1. Xu, Y.; Wang, N.; Tan, H.Y.; Li, S.; Zhang, C.; Feng, Y. Function of Akkermansia muciniphila in Obesity: Interactions With Lipid Metabolism, Immune Response and Gut Systems. Front. Microbiol. 2020, 11.
  2. Derrien, M.; Vaughan, E.E.; Plugge, C.M.; de Vos, W.M. Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int. J. Syst. Evol. Microbiol. 2004, 54, 1469–1476.
  3. Zhai, Q.; Feng, S.; Arjan, N.; Chen, W. A next generation probiotic, Akkermansia muciniphila. Crit. Rev. Food Sci. Nutr. 2019, 59, 3227–3236.
  4. Huang, K.; Wang, M.; Kulinich, A.; Yao, H.; Ma, H.; Reyes Martínez, J.E.; Duan, X.; Chen, H.; Cai, Z.P.; Flitsch, S.; et al. Biochemical characterisation of the neuraminidase pool of the human gut symbiont Akkermansia muciniphila. Carbohydr. Res. 2015, 415, 60–65.
  5. Ottman, N.; Huuskonen, L.; Reunanen, J.; Boeren, S.; Klievink, J.; Smidt, H.; Belzer, C.; de Vos, W.M. Characterization of Outer Membrane Proteome of Akkermansia muciniphila Reveals Sets of Novel Proteins Exposed to the Human Intestine. Front. Microbiol. 2016, 7, 1157.
  6. Collado, M.C.; Derrien, M.; Isolauri, E.; de Vos, W.M.; Salminen, S. Intestinal integrity and Akkermansia muciniphila, a mucin-degrading member of the intestinal microbiota present in infants, adults, and the elderly. Appl. Environ. Microbiol. 2007, 73, 7767–7770.
  7. Wang, L.; Christophersen, C.T.; Sorich, M.J.; Gerber, J.P.; Angley, M.T.; Conlon, M.A. Low relative abundances of the mucolytic bacterium Akkermansia muciniphila and Bifidobacterium spp. in feces of children with autism. Appl. Environ. Microbiol. 2011, 77, 6718–6721.
  8. Swidsinski, A.; Dörffel, Y.; Loening-Baucke, V.; Theissig, F.; Rückert, J.C.; Ismail, M.; Rau, W.A.; Gaschler, D.; Weizenegger, M.; Kühn, S.; et al. Acute appendicitis is characterised by local invasion with Fusobacterium nucleatum/necrophorum. Gut 2011, 60, 34–40.
  9. Dingemanse, C.; Belzer, C.; van Hijum, S.A.; Günthel, M.; Salvatori, D.; den Dunnen, J.T.; Kuijper, E.J.; Devilee, P.; de Vos, W.M.; van Ommen, G.B.; et al. Akkermansia muciniphila and Helicobacter typhlonius modulate intestinal tumor development in mice. Carcinogenesis 2015, 36, 1388–1396.
  10. Hansen, C.H.; Krych, L.; Nielsen, D.S.; Vogensen, F.K.; Hansen, L.H.; Sørensen, S.J.; Buschard, K.; Hansen, A.K. Early life treatment with vancomycin propagates Akkermansia muciniphila and reduces diabetes incidence in the NOD mouse. Diabetologia 2012, 55, 2285–2294.
  11. Pascale, A.; Marchesi, N.; Govoni, S.; Coppola, A.; Gazzaruso, C. The role of gut microbiota in obesity, diabetes mellitus, and effect of metformin: New insights into old diseases. Curr. Opin. Pharmacol. 2019, 49, 1–5.
  12. Dao, M.C.; Everard, A.; Aron-Wisnewsky, J.; Sokolovska, N.; Prifti, E.; Verger, E.O.; Kayser, B.D.; Levenez, F.; Chilloux, J.; Hoyles, L.; et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: Relationship with gut microbiome richness and ecology. Gut 2016, 65, 426–436.
  13. Remely, M.; Hippe, B.; Geretschlaeger, I.; Stegmayer, S.; Hoefinger, I.; Haslberger, A. Increased gut microbiota diversity and abundance of Faecalibacterium prausnitzii and Akkermansia after fasting: A pilot study. Wien. Klin. Wochenschr. 2015, 127, 394–398.
  14. Everard, A.; Matamoros, S.; Geurts, L.; Delzenne, N.M.; Cani, P.D. Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice. mBio 2014, 5, e01011-14.
  15. Schneeberger, M.; Everard, A.; Gómez-Valadés, A.G.; Matamoros, S.; Ramírez, S.; Delzenne, N.M.; Gomis, R.; Claret, M.; Cani, P.D. Akkermansia muciniphila inversely correlates with the onset of inflammation, altered adipose tissue metabolism and metabolic disorders during obesity in mice. Sci. Rep. 2015, 5, 16643.
  16. Caesar, R.; Tremaroli, V.; Kovatcheva-Datchary, P.; Cani, P.D.; Bäckhed, F. Crosstalk between Gut Microbiota and Dietary Lipids Aggravates WAT Inflammation through TLR Signaling. Cell Metab. 2015, 22, 658–668.
  17. Brahe, L.K.; Le Chatelier, E.; Prifti, E.; Pons, N.; Kennedy, S.; Hansen, T.; Pedersen, O.; Astrup, A.; Ehrlich, S.D.; Larsen, L.H. Specific gut microbiota features and metabolic markers in postmenopausal women with obesity. Nutr. Diabetes 2015, 5, e159.
  18. Everard, A.; Belzer, C.; Geurts, L.; Ouwerkerk, J.P.; Druart, C.; Bindels, L.B.; Guiot, Y.; Derrien, M.; Muccioli, G.G.; Delzenne, N.M.; et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc. Natl. Acad. Sci. USA 2013, 110, 9066–9071.
  19. Everard, A.; Lazarevic, V.; Derrien, M.; Girard, M.; Muccioli, G.G.; Neyrinck, A.M.; Possemiers, S.; Van Holle, A.; François, P.; de Vos, W.M.; et al. Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes 2011, 60, 2775–2786.
  20. Arora, A.; Behl, T.; Sehgal, A.; Singh, S.; Sharma, N.; Bhatia, T.; Sobarzo-Sanchez, E.; Bungau, S. Unravelling the Involvement of Gut Microbiota in Type 2 Diabetes Mellitus. Life Sci. 2021, 273, 119311.
  21. Santacruz, A.; Collado, M.C.; García-Valdés, L.; Segura, M.T.; Martín-Lagos, J.A.; Anjos, T.; Martí-Romero, M.; Lopez, R.M.; Florido, J.; Campoy, C.; et al. Gut microbiota composition is associated with body weight, weight gain and biochemical parameters in pregnant women. Br. J. Nutr. 2010, 104, 83–92.
  22. Karlsson, C.L.; Onnerfält, J.; Xu, J.; Molin, G.; Ahrné, S.; Thorngren-Jerneck, K. The microbiota of the gut in preschool children with normal and excessive body weight. Obesity 2012, 20, 2257–2261.
  23. Reunanen, J.; Kainulainen, V.; Huuskonen, L.; Ottman, N.; Belzer, C.; Huhtinen, H.; de Vos, W.M.; Satokari, R. Akkermansia muciniphila Adheres to Enterocytes and Strengthens the Integrity of the Epithelial Cell Layer. Appl. Environ. Microbiol. 2015, 81, 3655–3662.
  24. Rosario, D.; Benfeitas, R.; Bidkhori, G.; Zhang, C.; Uhlen, M.; Shoaie, S.; Mardinoglu, A. Understanding the Representative Gut Microbiota Dysbiosis in Metformin-Treated Type 2 Diabetes Patients Using Genome-Scale Metabolic Modeling. Front. Physiol. 2018, 9, 775.
  25. Al Khodor, S.; Reichert, B.; Shatat, I.F. The Microbiome and Blood Pressure: Can Microbes Regulate Our Blood Pressure? Front. Pediatr. 2017, 5, 138.
  26. Cani, P.D. Human gut microbiome: Hopes, threats and promises. Gut 2018, 67, 1716–1725.
  27. Ottman, N.; Reunanen, J.; Meijerink, M.; Pietilä, T.E.; Kainulainen, V.; Klievink, J.; Huuskonen, L.; Aalvink, S.; Skurnik, M.; Boeren, S.; et al. Pili-like proteins of Akkermansia muciniphila modulate host immune responses and gut barrier function. PLoS ONE 2017, 12, e0173004.
  28. Medina-Vera, I.; Sanchez-Tapia, M.; Noriega-López, L.; Granados-Portillo, O.; Guevara-Cruz, M.; Flores-López, A.; Avila-Nava, A.; Fernández, M.L.; Tovar, A.R.; Torres, N. A dietary intervention with functional foods reduces metabolic endotoxaemia and attenuates biochemical abnormalities by modifying faecal microbiota in people with type 2 diabetes. Diabetes Metab. 2019, 45, 122–131.
  29. Roshanravan, N.; Mahdavi, R.; Alizadeh, E.; Ghavami, A.; Rahbar Saadat, Y.; Mesri Alamdari, N.; Alipour, S.; Dastouri, M.R.; Ostadrahimi, A. The effects of sodium butyrate and inulin supplementation on angiotensin signaling pathway via promotion of Akkermansia muciniphila abundance in type 2 diabetes; A randomized, double-blind, placebo-controlled trial. J. Cardiovasc. Thorac. Res. 2017, 9, 183–190.
  30. Walker, J.M.; Eckardt, P.; Aleman, J.O.; da Rosa, J.C.; Liang, Y.; Iizumi, T.; Etheve, S.; Blaser, M.J.; Breslow, J.L.; Holt, P.R. The effects of trans-resveratrol on insulin resistance, inflammation, and microbiota in men with the metabolic syndrome: A pilot randomized, placebo-controlled clinical trial. J. Clin. Transl. Res. 2019, 4, 122–135.
  31. Allin, K.H.; Tremaroli, V.; Caesar, R.; Jensen, B.A.H.; Damgaard, M.T.F.; Bahl, M.I.; Licht, T.R.; Hansen, T.H.; Nielsen, T.; Dantoft, T.M.; et al. Aberrant intestinal microbiota in individuals with prediabetes. Diabetologia 2018, 61, 810–820.
  32. Khan, T.J.; Ahmed, Y.M.; Zamzami, M.A.; Siddiqui, A.M.; Khan, I.; Baothman, O.A.S.; Mehanna, M.G.; Kuerban, A.; Kaleemuddin, M.; Yasir, M. Atorvastatin Treatment Modulates the Gut Microbiota of the Hypercholesterolemic Patients. Omics 2018, 22, 154–163.
  33. Liu, F.; Ling, Z.; Xiao, Y.; Lv, L.; Yang, Q.; Wang, B.; Lu, H.; Zheng, L.; Jiang, P.; Wang, W.; et al. Dysbiosis of urinary microbiota is positively correlated with type 2 diabetes mellitus. Oncotarget 2017, 8, 3798–3810.
  34. Collado, M.C.; Isolauri, E.; Laitinen, K.; Salminen, S. Effect of mother’s weight on infant’s microbiota acquisition, composition, and activity during early infancy: A prospective follow-up study initiated in early pregnancy. Am. J. Clin. Nutr. 2010, 92, 1023–1030.
  35. Collado, M.C.; Laitinen, K.; Salminen, S.; Isolauri, E. Maternal weight and excessive weight gain during pregnancy modify the immunomodulatory potential of breast milk. Pediatr. Res. 2012, 72, 77–85.
  36. De la Cuesta-Zuluaga, J.; Mueller, N.T.; Corrales-Agudelo, V.; Velásquez-Mejía, E.P.; Carmona, J.A.; Abad, J.M.; Escobar, J.S. Metformin Is Associated With Higher Relative Abundance of Mucin-Degrading Akkermansia muciniphila and Several Short-Chain Fatty Acid-Producing Microbiota in the Gut. Diabetes Care 2017, 40, 54–62.
  37. Palleja, A.; Kashani, A.; Allin, K.H.; Nielsen, T.; Zhang, C.; Li, Y.; Brach, T.; Liang, S.; Feng, Q.; Jørgensen, N.B.; et al. Roux-en-Y gastric bypass surgery of morbidly obese patients induces swift and persistent changes of the individual gut microbiota. Genome Med. 2016, 8, 67.
  38. Yassour, M.; Lim, M.Y.; Yun, H.S.; Tickle, T.L.; Sung, J.; Song, Y.-M.; Lee, K.; Franzosa, E.A.; Morgan, X.C.; Gevers, D.; et al. Sub-clinical detection of gut microbial biomarkers of obesity and type 2 diabetes. Genome Med. 2016, 8, 17.
  39. Cortez, R.V.; Petry, T.; Caravatto, P.; Pessôa, R.; Sanabani, S.S.; Martinez, M.B.; Sarian, T.; Salles, J.E.; Cohen, R.; Taddei, C.R. Shifts in intestinal microbiota after duodenal exclusion favor glycemic control and weight loss: A randomized controlled trial. Surg. Obes. Relat. Dis. 2018, 14, 1748–1754.
  40. Depommier, C.; Everard, A.; Druart, C.; Plovier, H.; Van Hul, M.; Vieira-Silva, S.; Falony, G.; Raes, J.; Maiter, D.; Delzenne, N.M.; et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: A proof-of-concept exploratory study. Nat. Med. 2019, 25, 1096–1103.
  41. Grander, C.; Adolph, T.E.; Wieser, V.; Lowe, P.; Wrzosek, L.; Gyongyosi, B.; Ward, D.V.; Grabherr, F.; Gerner, R.R.; Pfister, A.; et al. Recovery of ethanol-induced Akkermansia muciniphila depletion ameliorates alcoholic liver disease. Gut 2018, 67, 891–901.
  42. Zhang, H.; DiBaise, J.K.; Zuccolo, A.; Kudrna, D.; Braidotti, M.; Yu, Y.; Parameswaran, P.; Crowell, M.D.; Wing, R.; Rittmann, B.E.; et al. Human gut microbiota in obesity and after gastric bypass. Proc. Natl. Acad. Sci. USA 2009, 106, 2365.
  43. Weir, T.L.; Manter, D.K.; Sheflin, A.M.; Barnett, B.A.; Heuberger, A.L.; Ryan, E.P. Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS ONE 2013, 8, e70803.
  44. Qin, J.; Li, Y.; Cai, Z.; Li, S.; Zhu, J.; Zhang, F.; Liang, S.; Zhang, W.; Guan, Y.; Shen, D.; et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012, 490, 55–60.
  45. Zhang, X.; Shen, D.; Fang, Z.; Jie, Z.; Qiu, X.; Zhang, C.; Chen, Y.; Ji, L. Human gut microbiota changes reveal the progression of glucose intolerance. PLoS ONE 2013, 8, e71108.
  46. Escobar, J.S.; Klotz, B.; Valdes, B.E.; Agudelo, G.M. The gut microbiota of Colombians differs from that of Americans, Europeans and Asians. BMC Microbiol. 2014, 14, 311.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
Video Production Service
Feedback